This Medical Letter review summarizes the newly available oral anticoagulants and compares them with commonly prescribed warfarin.
Direct-to-consumer advertisements continue to urge patients who take warfarin (Coumadin, and others) for atrial fibrillation to ask their doctors about the benefits of one or another of the newer oral anticoagulants.
Once a month, The Medical Letter provides a previously published article to JAMA to be republished.
Previous Publication: This article was published in The Medical Letter on Drugs and Therapeutics. April 11, 2016;58(1492):45-46. It is reprinted here with permission from ©The Medical Letter Inc.
For a free trial subscription to The Medical Letter, go to www.medicalletter.org/tmlj. The Medical Letter—Essential to your practice.
About The Medical Letter: The Medical Letter is a nonprofit organization that publishes biweekly new drug evaluations and treatment recommendations. The Medical Letter does not accept advertisements, gifts, grants, or donations. Financial support comes solely from sales of subscriptions, books, software, continuing education materials, and licenses.
Editors: Mark Abramowicz, MD, President; Gianna Zuccotti, MD, MPH, Vice President and Executive Editor; Jean-Marie Pflomm, PharmD, Editor in Chief